57800-76-7 Usage
General Description
5-Chloro-4-nitrothiophene-2-carboxylic acid methyl ester is a chemical compound that is used in various pharmaceutical and industrial applications. It is a methyl ester derivative of thieno[2,3-b]thiophene-2-carboxylic acid, which is a heterocyclic compound. This chemical is known for its unique properties and is commonly used as a building block in the synthesis of pharmaceuticals, agrochemicals, and biologically active compounds. It has also been studied for its potential use in the development of new drugs and therapeutic agents. The compound is important in organic synthesis and medicinal chemistry due to its versatility and potential pharmacological activities.
Check Digit Verification of cas no
The CAS Registry Mumber 57800-76-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,7,8,0 and 0 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 57800-76:
(7*5)+(6*7)+(5*8)+(4*0)+(3*0)+(2*7)+(1*6)=137
137 % 10 = 7
So 57800-76-7 is a valid CAS Registry Number.
InChI:InChI=1/C7H6ClNO4S/c1-2-13-7(10)5-3-4(9(11)12)6(8)14-5/h3H,2H2,1H3
57800-76-7Relevant articles and documents
BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS
-
, (2019/10/30)
The present invention relates to bumetanide derivatives of formula (I) as well as pharmaceutical compositions comprising these compounds for use in the treatment or prevention of diseases/disorders involving Na+- K+- 2CI- - cotransporters (NKCCs), and particularly for use in the treatment or prevention of hyperhidrosis.
Biaryl pyridine deubiquitinating enzyme inhibitor as well as preparation method and application thereof
-
, (2018/05/01)
The invention designs and synthesizes a biaryl pyridine deubiquitinating enzyme inhibitor. The biaryl pyridine deubiquitinating enzyme inhibitor has the structure which is shown as a general formula (I). The biaryl pyridine deubiquitinating enzyme inhibit
5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR
-
Page/Page column 122, (2008/06/13)
The present invention relates to a fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and